搜尋
Amarin Corporation PLC
AMRN添加自選
16.370USD
-0.100-0.61%
收盤 07/02, 16:00（美東）報價延遲15分鐘
343.44M總市值
虧損本益比TTM
關於 Amarin Corporation PLC 公司
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Amarin Corporation PLC簡介
公司代碼AMRN
公司名稱Amarin Corporation PLC
上市日期Apr 01, 1993
CEOBerg (Aaron D)
員工數量275
證券類型Depository Receipt
年結日Apr 01
公司地址WeWork One Central Plaza Dame Street
城市DUBLIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Ireland
郵編D02 K7K5
電話35316699020
網址https://amarincorp.com/
公司代碼AMRN
上市日期Apr 01, 1993
CEOBerg (Aaron D)
Amarin Corporation PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
234.16K
+95.00%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
8.42K
+4.75%
Mr. Jonathan N. Provoost
Mr. Jonathan N. Provoost
Executive Vice President, Chief Legal and Compliance Officer, Secretary
Executive Vice President, Chief Legal and Compliance Officer, Secretary
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael Torok
Mr. Michael Torok
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
234.16K
+95.00%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
8.42K
+4.75%
Mr. Jonathan N. Provoost
Mr. Jonathan N. Provoost
Executive Vice President, Chief Legal and Compliance Officer, Secretary
Executive Vice President, Chief Legal and Compliance Officer, Secretary
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
常見問題
Amarin Corporation PLC的前五大股東是誰？
Amarin Corporation PLC的前五大股東如下：Dr. David Keenan, Ph.D.
有多少機構持有Amarin Corporation PLC(AMRN)的股份？
截至2026Q1，共有280家機構持有Amarin Corporation PLC的股份，合計持有的股份價值約為4.71M，占公司總股份的22.72% 。與2025Q4相比，機構持股有所增加，增幅為-402415.00。